奥沙利铂联合卡培他滨方案治疗晚期胃癌的临床观察

目的 观察奥沙利铂联合卡培他滨方案治疗晚期胃癌的疗效及安全性。方法 对35例晚期胃癌患者采用奥沙利铂100mg／m^2，静脉滴注，第1天；卡培他滨2000mg／m^2／d分早晚2次餐后口服，第1—14天。每3周重复。每周期评价疗效同时记录不良反应。结果 全组35例病例中CR2例（5．71％），PR13例（37．14％），SD10例（28、57％），PD10例（28、57％），总有效率为42、86％。主要不良反应为中性粒细胞减少、手足综合症、腹泻、皮肤色素沉着．无治疗相关死亡。结论 奥沙利铂联合卡培他滨方案治疗晚期胃癌，疗效确切，多数患者耐受良好，值得进一步研究。

The Clinical Observation of Oxaliplatin in Combination with Capecitabine in Patients with Advanced Gastric Cancer

Objective To evaluate the efficacy and safety of Oxaliplatin in combination with capecitabine in treating advanced gastric cancer.Methods Thirty-five patients with advanced gastric cancer received chemotherapy: Oxaliplatin 100 mg/m~2 i.v,d1; combining oral capecitabine 2000mg/m~2.d (divided in two doses) d1-14; and repeated every 3 weeks.The efficacy and safety were assessed in every cycle.Results 2 cases (5.71%) achieved CR,13 cases (37.14%) had PR,10 cases (8.57%) had SD,10 cases (28.57%) had PD,with an overall response rate of 42.86%.The most common adverse effects were leucopenia,hand-foot syndrome,diarrhea and skin pigmentation.There was no treatment-related death.Conclusion Chemotherapy with oxaliplatin combined with capecitabine is effective and well-tolerated to the patients with advanced gastric cancer.